Detalhe da pesquisa
1.
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Ann Neurol
; 93(3): 604-614, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36401339
2.
Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
BMC Neurol
; 19(1): 116, 2019 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31176355
3.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
N Engl J Med
; 366(20): 1870-80, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22591293
4.
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.
J Neurol Neurosurg Psychiatry
; 85(11): 1190-7, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24532785
5.
Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.
Neurology
; 93(15): e1452-e1462, 2019 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31515290
6.
Repetitive transcranial magnetic stimulation over the primary motor cortex disrupts early boost but not delayed gains in performance in motor sequence learning.
Eur J Neurosci
; 28(6): 1216-21, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18783369
7.
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
CNS Drugs
; 32(12): 1183, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244406
8.
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
CNS Drugs
; 32(12): 1173-1181, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30143944
9.
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Mult Scler Relat Disord
; 22: 27-34, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29524759
10.
Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.
Int J MS Care
; 17(5): 236-43, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26472945
11.
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
J Neurol
; 260(5): 1388-95, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23292204
12.
Therapeutic use of high-frequency repetitive transcranial magnetic stimulation in stroke.
Stroke
; 38(2): 253; author reply 254, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17170361
13.
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
J Neurol
; 259(5): 898-905, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22008873
14.
Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.
Neurorehabil Neural Repair
; 25(7): 672-9, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21436388
15.
Early boost and slow consolidation in motor skill learning.
Learn Mem
; 13(5): 580-3, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16980543